Results of a prospective randomized trial using DTIC and interferon as adjuvant therapy for stage I malignant melanoma

Kerin, Michael J.; Gillen, Peter; Monson, J. R. T.; Wilkie, Jane Riblett; Keane, Fergus; Tanner, W. A.

doi:10.1016/s0748-7983(95)97305-2

Cited by 10 publications

(1 citation statement)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Early randomized trials of adjuvant therapy in melanoma using dacarbazine (e.g. Kerin et al, 1995), combination chemotherapy (e.g. Meisenberg et al, 1993), bacille CalmetteGuerin (BCG; Tan and Ho, 1993) and other modalities, including levamisole (e.g.…”

Section: Biological Agents Hold the Greatest Promise As Systemic Therapymentioning

confidence: 99%

Adjuvant therapy for melanoma: How should we respond to high-dose interferon?

Takats

Williams²,

Hawkins³

1998

Br J Cancer

View full text Add to dashboard Cite

Section: Biological Agents Hold the Greatest Promise As Systemic Therapymentioning

confidence: 99%

Adjuvant therapy for melanoma: How should we respond to high-dose interferon?

Takats

Williams²,

Hawkins³

1998

Br J Cancer

View full text Add to dashboard Cite

Interferon alpha for the adjuvant treatment of cutaneous melanoma

Mocellin

Lens

Pasquali

et al. 2013

Cochrane Database of Systematic Reviews

139

View full text Add to dashboard Cite

Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma

Verma

Quirt

McCready

et al. 2006

Cancer

113

View full text Add to dashboard Cite

The authors examined the role of systemic adjuvant therapy in patients with high-risk, resected, primary melanoma. Outcomes of interest included overall survival, disease-free survival, adverse effects, and quality of life. A systematic review of the literature was conducted to locate randomized controlled trials, practice guidelines, meta-analyses, and reviews published between 1980 and 2004.Thirty-seven randomized controlled trials, 2 meta-analyses, and 1 systematic review were identified that investigated interferon, levamisole, vaccine, or chemotherapy as adjuvant therapy. For high-dose interferon-␣, the results from 3 randomized trials conducted by the Eastern Cooperative Oncology Group were pooled, and a metaanalysis of 2-year death rates yielded a risk ratio of 0.85 (95% confidence interval, 0.73-0.99; P ϭ .03). Five randomized trials comparing lowdose interferon-␣ with observation only after surgery did not detect a statistically significant improvement in overall survival. A metaanalysis of 4 levamisole trials did not demonstrate a significant survival benefit for levamisole over control; similarly, no survival benefit was demonstrated by data from randomized controlled trials with vaccines (9 trials) or with chemotherapy (10 trials). In this review of the available literature, no systemic adjuvant therapy was identified that conferred a significant overall survival benefit in patients with high-risk, resected, primary melanoma. However, high-dose interferon should be considered in the treatment of these patients, because such therapy is associated with a significant improvement in disease-free survival and a reduction in 2-year mortality. Until the results of ongoing trials are available, the authors could not state with confidence whether such therapy benefits patients with microscopically detected, sentinel lymph node-positive disease.

show abstract

Results of a prospective randomized trial using DTIC and interferon as adjuvant therapy for stage I malignant melanoma

Cited by 10 publications

References 7 publications

Adjuvant therapy for melanoma: How should we respond to high-dose interferon?

Adjuvant therapy for melanoma: How should we respond to high-dose interferon?

Interferon alpha for the adjuvant treatment of cutaneous melanoma

Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma

Contact Info

Product

Resources

About